Duopharma Biotech expects longer-term revenue recovery

KUALA LUMPUR: Duopharma Biotech Bhd is looking at a gradual recovery in revenue as it continues to strengthen its portfolio with high-value innovative offerings and niche products.

Group managing director Leonard Ariff Abdul Shatar said the group will focus on the ethical and consumer healthcare segments, while weathering persistent industry-wide challenges.